Search results
Showing 256 to 270 of 1003 results for public health medicine & health
The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.
Awaiting development Reference number: GID-TA11437 Expected publication date: TBC
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]
In development Reference number: GID-TA10024 Expected publication date: 28 June 2017
Biographies and registered interests for members of the Technology Appraisal Committee A
Our board sets out our strategic priorities and policies. It has 2 sub-committees, the audit and risk assurance committee and the remuneration committee.
Depemokimab for treating severe eosinophilic asthma in people 12 years and over [ID6447]
In development Reference number: GID-TA11553 Expected publication date: TBC
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769]
Awaiting development Reference number: GID-TA11088 Expected publication date: TBC
Read the biographies of our medical technologies advisory committee members.
Psychosis and schizophrenia in adults: prevention and management (CG178)
This guideline covers recognising and managing psychosis and schizophrenia in adults. It aims to improve care through early recognition and treatment, and by focusing on long-term recovery. It also recommends checking for coexisting health problems and providing support for family members and carers.
This quality standard covers support and treatment to stop smoking and stop using smokeless tobacco, and harm-reduction approaches for people who are not ready to stop in one go. It describes high-quality care in priority areas for improvement.
View quality statements for QS207Show all sections
Sections for QS207
- Quality statements
- Quality statement 1: Identifying people who use tobacco
- Quality statement 2: Advice
- Quality statement 3: Tobacco cessation support and treatment
- Quality statement 4: Harm-reduction approach
- Quality statement 5: Treatment to stop smoking in hospital
- Update information
- About this quality standard
Awaiting development Reference number: GID-TA11040 Expected publication date: TBC
This guideline covers identifying, treating and managing depression in people aged 18 and over. It recommends treatments for first episodes of depression and further-line treatments, and provides advice on preventing relapse, and managing chronic depression, psychotic depression and depression with a coexisting diagnosis of personality disorder.
Depression in children and young people: identification and management (NG134)
This guideline covers identifying and managing depression in children and young people aged 5 to 18 years. Based on the stepped-care model, it aims to improve recognition and assessment and promote effective treatments for mild and moderate to severe depression.
Awaiting development Reference number: GID-TA11705 Expected publication date: TBC
Awaiting development Reference number: GID-TA11404 Expected publication date: TBC